CanSino Biologics, Inc. Class H (HK:6185) has released an update.
CanSino Biologics Inc. has released its unaudited interim financial results for the first half of the year ended June 30, 2024, indicating a noteworthy period for the company and its subsidiaries. The announcement, which complies with the Hong Kong Stock Exchange listing rules, has been reviewed and confirmed by the Board and the audit committee. Investors and shareholders can find the detailed report on the company’s website and it will also be dispatched in printed form to those who have opted for it.
For further insights into HK:6185 stock, check out TipRanks’ Stock Analysis page.
